



Emerging Importance of Ceramides in Cardiovascular Disorders

¹Manisha Devi, ¹Nisha*

¹School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab

Keywords

Cell signaling, neurodegeneration, homeostasis, apoptosis, proliferation, atherosclerosis, inflammatory signals.

Abstract

Sphingolipid consist of the sphingoid base backbone that are synthesized de novo from serine and fatty acyl-CoA. Then converted into more complex compound ceramides, phosphosphingolipid, glycosphingolipids and protein adduct. Sphingolipid are group of complex fats that help build and support cell membrane, structure and signaling. Ceramide a central molecule in sphingolipid metabolism, consist of sphingosine and fatty acid. Ceramide actively helps control various important cellular functions including apoptosis, proliferation, growth, death and response to stress. When ceramide levels are out of balance, it can contribute to diseases such as cancer, neurodegeneration, metabolic disorders, its significance in cellular homeostasis and human health recent years there's been growing interest in how ceramide contribute cardiovascular diseases. Focusing how ceramide related during various heart related condition such as hypertension, heart attack, atherosclerosis. We explore the role of ceramide in cardiovascular diseases discuss its potential as both diagnostic biomarker and therapeutic target. Ceramide production increases in response to high blood sugar level and inflammatory signals like tumor necrosis factor TNF- α .

*Corresponding Author:

Ms. Nisha (sharmanishii8gmail.com)

Article Info

Received: 12 November 2026, Received in revised form: 28 March 2026, Accepted: 28 March 2026, Available online: 31 March 2026; Volume: 2; Issue: 1; Pages: 01-13.

ISSN: 3049-2955/The authors © 2026, under exclusive license to the Sprout Publication

DOI: <https://doi.org/10.63785/2026.2.1.0113>

1. Introduction

Lipid is a group including oilseed. Sphingolipid is a class of lipids. It is a lipid molecule that contains a sphingolipid backbone is known as component. Sphingolipid-based and glycerol-based phospholipids are major components. Structural ceramides are a family of waxy lipid molecules contained of sphingosine & fatty acid merged by amide bond [1]. The mostly founded ceramides are fatty acyl chains of carbon atoms or longer and are among the least polar more hydrophobic lipid membrane. Ceramides are known to be potent inhibitors of cell growth & effective promoters of apoptosis in most cell types, involves, apoptosis, radiation, chemotherapy effect on tumor, bacterial a viral infection heart, UVA injury [2].

2. Sphingolipid Metabolism

Sphingolipid metabolism is a complex network of biosynthetic and degradative pathways that regulate the formation and turnover of bioactive lipids

essential for cell structure and signaling. It begins with the de novo synthesis of ceramide from serine and fatty acyl-CoA in the endoplasmic reticulum, which serves as the central molecule in this pathway [3]. Ceramide can be further converted into sphingomyelin, glycosphingolipids (such as cerebrosides and gangliosides), or phosphorylated to form ceramide-1-phosphate. In the catabolic pathway, sphingolipids are broken down into sphingosine, which can be phosphorylated to sphingosine-1-phosphate (S1P), a potent signaling molecule involved in cell proliferation, survival, and migration. The dynamic balance between ceramide (pro-apoptotic) and S1P (pro-survival) plays a critical role in regulating cellular fate and is particularly important in diseases such as cancer, neurodegeneration, and inflammation [4].




Figure 1: Overview of sphingolipid metabolism.

Figure 1 illustrates the biosynthesis and degradation of ceramide, an important bioactive lipid. The process begins with basic building blocks such as serine and palmitoyl-CoA in the de novo pathway (yellow). Ceramide can also be generated from sphingomyelin via the sphingomyelinase (SMase) pathway (blue) [5]. Once formed, ceramide may undergo degradation through the catabolic pathway (purple), producing sphingosine and other metabolites. Additionally, ceramide can be converted into more complex sphingolipids, such as cerebroside and gangliosides, through the glycosylation pathway (green) [6].

3. Key Steps for Sphingolipid Biosynthesis

3.1. Synthesis of Ceramide

The foundation of sphingolipid biosynthesis starts with ceramide, a lipid molecule central to the structure of sphingolipids. Sphingosine is produced from serine and palmitoyl-CoA. First, serine combines with palmitoyl-CoA to form 3-ketodihydrosphingosine [7]. This intermediate is reduced to dihydrosphingosine, which is then converted into sphingosine. The final step in ceramide synthesis involves acylating sphingosine with a fatty acid, commonly palmitoyl-CoA, to produce ceramide [8].




Figure 2: Structure of Ceramide.

Ceramides are fatty acid derived from of sphingoid bases. These fatty acids are typically saturated and mono-unsaturated chain with 14-26 carbon atoms. Ceramide kinases were first identified in brain synaptic

3.2 Formation of Complex Sphingolipids

Ceramide serves as a key precursor for the formation of complex sphingolipids through specific biochemical modifications. It combines with phosphatidylcholine to produce sphingomyelin, an essential component of the plasma membrane, particularly abundant in nerve cells where it contributes to membrane structure and function [9]. Additionally, ceramide can undergo glycosylation, where sugar moieties are attached to form glycosphingolipids. These include cerebroside, which contain a single sugar unit, and more complex gangliosides that possess elaborate carbohydrate chains often incorporating sialic acid. These complex sphingolipids play crucial roles in cell recognition, signaling, and membrane stability [10].

3.3 Modification and Transport

Once formed, these complex sphingolipids undergo modification and are transported to the Golgi apparatus, where additional steps, like adding more sugars or phosphate groups, can take place. These lipids are then incorporated into cell membranes, especially in the plasma membrane, where they play key roles in cell signaling, cell recognition, and structural stability [11].

4. Ceramide Structure and Function

Ceramide are a family of waxy lipid molecules composed of sphingosine and fatty acid linked by amide bond. The mostly founded ceramide is fatty acyl chain of carbon atom or longer, are among least polar, more hydrophobic lipid membrane. Long chain ceramide (fatty acid C12) belongs to the category of "non-swelling amphiphiles". Ceramide (N-acyl sphingosine) known as decades as intermediates in sphingolipid metabolism and as minor membranes component [12].

Figure 2 illustrates the structural organization of ceramide, composed of a sphingosine backbone linked to a fatty acid via an amide bond. This structure imparts hydrophobic properties, enabling ceramide to integrate into lipid bilayers. It plays a crucial role in maintaining membrane integrity and regulating cellular signaling processes [13].

vesicles. Ceramides are known to be potent inhibitors of cell growth and effective promoter of apoptosis in most cell type. Ceramide is related to the regulation of cell proliferation, differentiation, apoptosis, radiation

and chemotherapy effects on tumours, bacterial and viral infection, and heart UVA injury [14].

4.1 Amino-Azido Ceramide

Amino-azido ceramide is a synthetic ceramide analog modified with amino and azido functional groups, enabling bioorthogonal labeling and imaging. It is

widely used in lipidomics to study ceramide metabolism, intracellular trafficking, and protein interactions through click chemistry, providing insights into cellular signaling and disease mechanisms [15].




Figure 3: Structure of amino-azido ceramide.

Figure 3 illustrates the chemical structure of amino-azido ceramide, a modified ceramide analog featuring both amino and azido functional groups. The long hydrophobic hydrocarbon chain is linked to a sphingoid backbone via an amide bond, while the azide group enables bioorthogonal labeling. This structural modification allows its application in click chemistry for studying ceramide metabolism, localization, and lipid–protein interactions in biological systems [15].

4.2 Ceramide Alkyne

Ceramide alkyne is a chemically modified ceramide

analog that contains an alkyne functional group, enabling its use in bioorthogonal click chemistry for detection and visualization. It is widely applied in lipid research to study ceramide metabolism, intracellular localization, and protein–lipid interactions. By incorporating into cellular membranes, ceramide alkyne helps track sphingolipid dynamics and signaling pathways. This probe is particularly valuable in investigating disease mechanisms, including cancer, metabolic disorders, and neurodegenerative conditions [16].




Figure 4: Structure of ceramide alkyne.

Figure 4 illustrates the structure of ceramide alkyne, a modified ceramide analog characterized by the presence of an alkyne functional group within its hydrocarbon chain. The molecule retains the sphingoid backbone linked to a fatty acid via an amide bond, while the alkyne group enables bioorthogonal click chemistry. This modification allows its use in studying ceramide distribution, metabolism, and lipid–protein interactions within cellular systems [17].

4.3 Ceramide-azide

Ceramide-azide is a synthetic ceramide analog containing an azide functional group, widely used in bioorthogonal chemistry for labelling and detection. It enables visualization of ceramide distribution, trafficking, and metabolism within cells via click chemistry reactions. This probe is valuable for studying sphingolipid signaling, membrane dynamics, and disease-related processes, including cancer, metabolic disorders, and neurodegeneration [15].




Figure 5: Structure of ceramide-azide.

Figure 5 illustrates the structure of ceramide-azide, a modified ceramide analog containing an azide functional group at the terminal end of the hydrocarbon chain. The molecule retains the characteristic sphingoid backbone with hydroxyl and amino groups, enabling membrane integration. The azide moiety facilitates bioorthogonal click chemistry, allowing visualization, tracking, and analysis of ceramide metabolism and interactions in biological systems [18].

4.4 Pac-ceramide

Pac-ceramide is a photoactivatable and clickable ceramide analog designed for studying lipid–protein interactions. It contains photoreactive and bioorthogonal groups that enable crosslinking with target proteins upon light activation. Widely used in lipidomics, it helps investigate ceramide localization, signaling pathways, and molecular mechanisms involved in various diseases [19].




Figure 6: Structure of Pac-ceramide.

Figure 6 illustrates the structure of Pac-ceramide, a photoactivatable ceramide analog designed for advanced biochemical studies. It contains a sphingoid backbone linked to a fatty acid chain along with photoreactive and clickable functional groups. These modifications enable light-induced crosslinking with interacting proteins and subsequent detection via click chemistry, facilitating the study of ceramide-mediated signaling pathways and lipid–protein interactions [20].

4.5 Pac-dihydroceramide

Pac-dihydroceramide is a modified dihydroceramide analog incorporating photoactivatable and clickable functional groups for advanced lipid research. It enables covalent crosslinking with interacting proteins upon light activation and subsequent detection via click chemistry. This probe is useful for studying dihydroceramide metabolism, intracellular trafficking, and lipid–protein interactions, providing insights into cellular signaling pathways and disease mechanisms, particularly in cancer and metabolic disorders [21].




Figure 7: Structure of Pac-dihydroceramide.

Figure 7 illustrates the structure of Pac-dihydroceramide, a modified dihydroceramide analog incorporating photoreactive and clickable functional groups. The molecule retains the sphingoid backbone linked to a fatty acid via an amide bond, while

additional functional groups enable photo-crosslinking and click chemistry. This design facilitates the study of dihydroceramide metabolism, localization, and lipid–protein interactions in cellular systems [19].

4.6 Pac-ceramide-C6

Pac-ceramide-C6 is a short-chain, photoactivatable ceramide analog designed for advanced lipidomics and cellular studies. It contains clickable and photoreactive groups that allow covalent crosslinking with interacting proteins upon light activation, followed by detection using click chemistry. Due to its

C6 acyl chain, it exhibits improved cellular uptake and membrane permeability. Pac-ceramide-C6 is widely used to investigate ceramide metabolism, intracellular localization, lipid–protein interactions, and signaling pathways, offering valuable insights into disease mechanisms such as cancer and metabolic disorders [22].




Figure 8: Structure of Pac-Ceramide-C6.

Figure 8 illustrates the structure of pac-ceramide-C6, a short-chain, photoactivatable ceramide analog. It retains the characteristic sphingoid backbone and amide-linked fatty acid, while incorporating photoreactive and clickable functional groups. The shorter C6 acyl chain enhances cellular uptake and membrane permeability, making it a valuable probe for studying ceramide metabolism, localization, and lipid–protein interactions [23].

5. Role of Ceramide in Cell Signalling

Ceramides play a crucial role in regulating various cellular signaling pathways that control cell fate and function. They are key mediators of apoptosis, where increased ceramide levels under stress conditions activate signaling cascades involving proteins such as caspases, leading to programmed cell death [24]. In addition, ceramides influence cell proliferation and differentiation by modulating kinases like protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs), thereby altering gene expression. During cellular stress, ceramides help initiate adaptive responses, either promoting survival or triggering cell death if damage is irreversible. Beyond these roles, ceramides act as second messengers, modulating membrane properties and interacting with proteins to regulate signaling processes. Furthermore, elevated ceramide levels are associated with impaired insulin signaling, reducing glucose uptake and contributing to insulin resistance and metabolic disorders such as type 2 diabetes [25].

6. Ceramide & Disease Pathogenesis

Ceramides are a type of lipid (fat) molecule made up of sphingosine and a fatty acid. They're like the unsung heroes of our cells playing critical roles in maintaining the structure of cell membranes, sending important signals within cells, and regulating key cellular activities. But when things go wrong with ceramide metabolism, it can trigger or worsen a range of diseases [26].

6.1. Cardiovascular Diseases

Elevated ceramide levels play a significant role in cardiovascular diseases, particularly in atherosclerosis and heart failure. In atherosclerosis, increased

ceramide accumulation promotes inflammation, damages the endothelial lining of blood vessels, and stimulates the migration of smooth muscle cells, leading to plaque formation and arterial blockage. In heart failure, excess ceramides accumulate in cardiomyocytes and induce apoptosis, resulting in progressive weakening of the heart muscle. Together, these effects contribute to impaired cardiac function and increased risk of adverse cardiovascular events [27], [28].

6.2. Metabolic Disorders

Ceramides play a critical role in metabolic disorders such as insulin resistance, type 2 diabetes, and obesity. They interfere with insulin signaling pathways, impairing glucose uptake and reducing cellular responsiveness to insulin, which contributes to the development of insulin resistance and type 2 diabetes [29]. Additionally, ceramide accumulation in adipose tissue and skeletal muscle is associated with chronic low-grade inflammation, disrupting normal metabolic processes and further exacerbating insulin resistance and metabolic dysfunction [30].

6.3. Cancer

Ceramides exhibit a dual role in cancer, influencing both tumour suppression and progression. While they can induce apoptosis in certain contexts, alterations in ceramide metabolism in some cancers promote cell survival, proliferation, and tumour growth. These changes may also contribute to resistance against therapeutic interventions. Furthermore, dysregulated ceramide pathways are closely associated with chemoresistance, reducing the effectiveness of chemotherapy and posing a major challenge in cancer treatment [31].

6.4. Neurodegenerative Diseases

Ceramides are strongly implicated in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. In Alzheimer's disease, ceramide accumulation in the brain is associated with neuroinflammation, impaired neuronal communication, and progressive neuronal death. Similarly, in Parkinson's disease, elevated ceramide levels can activate apoptotic pathways that damage

dopamine-producing neurons, leading to motor dysfunction. These mechanisms highlight the critical role of ceramide dysregulation in neurodegeneration [32].

6.5 Inflammatory and Autoimmune Diseases

Ceramides play a significant role in inflammatory and autoimmune disorders by modulating immune cell function. They contribute to chronic inflammation by influencing key immune pathways, which are central to diseases such as rheumatoid arthritis and inflammatory bowel disease. Additionally, ceramides can activate immune cells, including T cells and macrophages, thereby enhancing autoimmune

responses in which the body mistakenly attacks its own tissues, leading to disease progression [33].

6.6 Skin Disorders

Ceramides are essential for maintaining the integrity of the skin barrier, and their deficiency is closely associated with dermatological disorders such as atopic dermatitis and psoriasis. Reduced ceramide levels weaken the skin's protective barrier, increasing susceptibility to irritants, allergens, and microbial infections. This disruption promotes inflammation and contributes to the development and progression of skin conditions, including eczema and psoriasis [34].

Table 1: Role of Ceramide in Diseases and Biological Functions.

S. No.	Disease/Condition	Role of Ceramide	Mechanism	Clinical/Research Significance	References
1.	Atherosclerosis	Promotes plaque formation	LDL aggregation	CVD biomarker	[35], [36]
2.	Heart failure	Induces apoptosis	Caspase activation	Cardiac dysfunction	[37]
3.	Hypertension	Impairs vasodilation	↓ Nitric oxide	Vascular damage	[38]
4.	Endothelial dysfunction	Disrupts vascular lining	ROS generation	Early CVD marker	[39]
5.	Myocardial infarction	Increases cell death	Oxidative stress	Heart attack risk	[40], [41]
6.	Stroke	Enhances neuronal injury	Inflammation	Brain damage	[42], [43]
7.	Insulin resistance	Blocks insulin signaling	Akt inhibition	Diabetes onset	[44]
8.	Type 2 diabetes	Reduces glucose uptake	Metabolic disruption	Therapeutic target	[45], [46]
9.	Obesity	Promotes lipid accumulation	Inflammation	Metabolic syndrome	[47]
10.	Fatty liver disease	Lipid imbalance	Hepatic stress	Liver dysfunction	[48]
11.	Cancer (general)	Dual role	Apoptosis modulation	Drug target	[49], [50]
12.	Breast cancer	Promotes survival pathways	Chemoresistance	Therapy resistance	[51], [52]
13.	Colon cancer	Alters cell proliferation	Signal dysregulation	Tumor progression	[53], [54]
14.	Lung cancer	Enhances tumor growth	Metabolic shift	Prognostic marker	[49]
15.	Chemoresistance	Reduces drug efficacy	Altered signaling	Treatment failure	[55]
16.	Alzheimer's disease	Neuronal degeneration	Amyloid formation	Neurodegeneration marker	[56]
17.	Parkinson's disease	Dopaminergic neuron loss	Apoptosis	Motor dysfunction	[57], [58]
18.	Multiple sclerosis	Demyelination	Immune activation	Neuroinflammation	[59]
19.	Neuroinflammation	Activates immune cells	Cytokine release	Brain disorders	[60]
20.	Cognitive decline	Impairs neurons	Synaptic dysfunction	Aging biomarker	[61], [62]
21.	Rheumatoid arthritis	Promotes inflammation	TNF-α release	Autoimmune disease	[63], [64]
22.	Inflammatory bowel disease	Chronic inflammation	Immune dysregulation	GI disorder	[65]

23.	Sepsis	Systemic inflammation	Cytokine storm	Critical illness	[66]
24.	Asthma	Airway inflammation	Immune activation	Respiratory disorder	[67], [68]
25.	Psoriasis	Skin barrier disruption	Lipid imbalance	Dermatological therapy	[69]
26.	Eczema	Reduced ceramide levels	Barrier dysfunction	Skin treatment	[70]
27.	Dermatitis	Inflammation	Immune response	Skin damage	[71]
28.	Aging	Cell senescence	Oxidative stress	Aging marker	[72], [73]
29.	Apoptosis	Cell death induction	Caspases	Cancer therapy	[74], [75]
30.	Cell proliferation	Growth regulation	PKC/MAPK pathways	Tissue development	[76]
31.	Cell differentiation	Controls maturation	Gene expression	Development biology	[77]
32.	Oxidative stress	ROS production	Mitochondrial damage	Disease progression	[78], [79]
33.	Mitochondrial dysfunction	Energy imbalance	ETC inhibition	Metabolic diseases	[80]
34.	Lipoprotein aggregation	LDL clustering	Plaque formation	Atherosclerosis	[81]
35.	Immune activation	T-cell stimulation	Cytokine signaling	Autoimmune diseases	[82], [83]
36.	Signal transduction	Second messenger role	Protein interaction	Cell communication	[84], [85]
37.	Membrane integrity	Structural lipid	Bilayer stability	Cell survival	[86]
38.	Lipid metabolism	Central metabolite	Sphingolipid pathway	Drug target	[87], [88]
39.	Stress response	Adaptive signaling	Survival/apoptosis	Cellular homeostasis	[89]
40.	Tumor suppression	Induces apoptosis	Pro-death signaling	Anti-cancer therapy	[51]

7. Therapeutic Strategies Targeting Ceramide

7.1. Combination Therapies

Integrating ceramide modulators with conventional chemotherapy has shown promising results in enhancing anticancer effects. By combining chemotherapeutic agents with exogenous ceramide or ceramide-modulating compounds, researchers have found ways to overcome multidrug resistance and reduce systemic toxicity. This approach leverages ceramide's role in disrupting cell survival signaling and triggering apoptotic pathways, making cancer cells more susceptible to treatment [90].

7.2. Ceramide Nanodelivery Systems

Advanced nanotechnology enables the targeted delivery of ceramide to tumor sites using nanoliposomal formulations. This method improves therapeutic efficacy while minimizing side effects. Studies have shown that nanoliposomal ceramide effectively inhibits hepatocellular carcinoma growth, induces tumor cell apoptosis, and reduces vascularization, making it a promising strategy in cancer treatment [91].

7.3. Enzyme Inhibitors

Targeting enzymes involved in ceramide metabolism, such as sphingomyelinases, can help regulate ceramide degradation, thereby sustaining its tumour-suppressive effects. By maintaining elevated ceramide

levels within cancer cells, this approach enhances the compound's ability to induce cell death and inhibit tumour progression [92].

8. Ceramide in CVDs

Ceramides, a class of sphingolipids, have emerged as key contributors to cardiovascular disease (CVD) through multiple interconnected mechanisms. They promote atherosclerosis by enhancing the aggregation and retention of low-density lipoprotein (LDL) cholesterol within arterial walls, leading to plaque formation [93]. Ceramides also induce endothelial dysfunction by activating protein phosphatase 2A (PP2A), which impairs nitric oxide production and vascular relaxation. Additionally, they contribute to oxidative stress by inhibiting mitochondrial electron transport chain activity, resulting in increased production of reactive oxygen species (ROS). Furthermore, elevated ceramide levels are strongly associated with heightened inflammatory responses, collectively driving the progression of cardiovascular diseases [81].

9. Mechanism of ceramide mediate CVDs

Ceramides, a type of bioactive sphingolipid, play a critical role in the development of cardiovascular diseases (CVD) through several interconnected pathways. Elevated ceramide levels have been linked to inflammation, oxidative stress, endothelial

dysfunction, and lipoprotein aggregation-all of which contribute to atherosclerosis and other heart conditions [94].

9.1 Inflammation and Atherosclerosis

Increased ceramide levels promote the release of inflammatory cytokines like tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6). These cytokines activate pathways such as NF- κ B, triggering inflammatory responses that impair blood vessel function and contribute to plaque buildup. Additionally, ceramides enhance the aggregation of low-density lipoproteins (LDL) in arterial walls, accelerating the formation of atherosclerotic plaques [95].

9.2 Oxidative Stress and Endothelial Dysfunction

Ceramides play a role in oxidative stress by stimulating the production of reactive oxygen species (ROS), including superoxide radicals (O_2^-). This process activates enzymes like NADPH oxidase and disrupts endothelial nitric oxide synthase (eNOS), reducing the availability of nitric oxide (NO). Since NO is crucial for blood vessel relaxation, its depletion leads to impaired vasodilation and endothelial dysfunction a key factor in many cardiovascular disorders [96].

9.3 Apoptosis of Cardiovascular Cells

High ceramide concentrations can trigger programmed cell death (apoptosis) in both endothelial cells and heart muscle cells (cardiomyocytes). This loss of essential cells weakens blood vessel integrity and cardiac function, increasing the risk of heart disease [97].

9.4 Lipoprotein Aggregation and Plaque Formation

Ceramide-enriched LDL particles have a greater tendency to aggregate, making them more likely to get trapped in the arterial walls. This promotes foam cell formation and accelerates plaque development-hallmarks of atherosclerosis [98].

10. Targeting Ceramide Metabolism

Given their central role in the pathogenesis of cardiovascular diseases (CVD), ceramides have emerged as promising therapeutic targets for intervention. Dysregulated ceramide metabolism contributes to key pathological processes such as inflammation, oxidative stress, endothelial dysfunction, and apoptosis, all of which accelerate cardiovascular damage. Therefore, strategies aimed at modulating ceramide levels offer significant potential in reducing disease progression and improving clinical outcomes [99]. One major approach involves inhibiting enzymes responsible for ceramide synthesis, such as serine palmitoyltransferase and ceramide synthases, thereby lowering intracellular ceramide accumulation. Another strategy focuses on enhancing ceramide degradation or conversion into less harmful metabolites, such as sphingosine-1-phosphate, which exerts protective effects on cardiovascular function. Pharmacological agents and small-molecule inhibitors targeting these pathways

are currently being explored for their therapeutic efficacy [100].

In addition to drug-based approaches, lifestyle modifications, including dietary interventions rich in unsaturated fatty acids and regular physical activity, have been shown to influence ceramide metabolism and reduce circulating ceramide levels [101]. Furthermore, advancements in nanotechnology-based drug delivery systems may enable targeted modulation of ceramide pathways with improved precision and reduced side effects. Overall, targeting ceramide metabolism represents a promising and multifaceted strategy for the prevention and treatment of cardiovascular diseases, although further clinical studies are required to validate its long-term safety and effectiveness [102].

11. Therapeutic Implications

11.1. Enzyme Inhibition

Certain medications can help lower ceramide levels by inhibiting enzymes like serine palmitoyltransferase and sphingomyelinases, which are involved in ceramide production. Research suggests that reducing ceramide levels in this way may slow the progression of atherosclerosis and improve overall cardiovascular health [103].

11.2. Lifestyle Modifications

Adopting a Mediterranean diet rich in monounsaturated and omega-3 polyunsaturated fatty acids-has been shown to naturally lower ceramide levels. This dietary approach not only supports heart health but also helps regulate ceramide metabolism, potentially reducing the risk of cardiovascular disease [104].

11.3 Biomarker Utilization

Elevated ceramide levels in the bloodstream have been identified as reliable predictors of cardiovascular events. Integrating ceramide measurements into routine clinical assessments could improve risk prediction and allow for more personalized treatment strategies [105].

Conclusion

The growing understanding of ceramides' role in cardiovascular disease (CVD) reveals their significant impact on heart health. Ceramides, a type of lipid, play a critical part in processes like inflammation, cell death (apoptosis), and fat metabolism all of which contribute to the development of heart disease. Higher ceramide levels have been linked to key problems such as the hardening of arteries (atherosclerosis), poor blood vessel function (endothelial dysfunction), and heart attacks (myocardial infarction). Recent research shows that ceramides act as bioactive molecules that can influence the function of smooth muscle cells in blood vessels, increase oxidative stress, and worsen the build-up of plaque in the arteries. This suggests that ceramides could not only serve as indicators of cardiovascular risk but may also be potential targets for treatment. Approaches that reduce ceramide levels or regulate their activity could offer new ways to

prevent or treat heart disease. However, more research is needed to fully understand how ceramides contribute to heart disease and how we can apply these findings in clinical settings. Overall, ceramides are an exciting area of research, with the potential to greatly improve how we manage and prevent cardiovascular diseases.

Acknowledgment

The authors sincerely acknowledge their respective institutions for providing the necessary facilities and academic support to carry out this review work. The authors are also grateful to colleagues and peers for their constructive suggestions during the preparation of the manuscript.

Author Contribution

MD: Writing the original manuscript, Proof reading;

N: Writing reviewing and editing, visualization and data curation.

Conflict of Interest

The authors declare no conflict of interest.

Source of Funding

There is no funding available to conduct this study.

AI Declarations

The authors declare that they used AI language tools (ChatGPT and Grammarly Premium) to enhance this manuscript's linguistic clarity and readability. They carefully reviewed and edited all generated text to ensure accuracy and alignment with the research's intended meaning.

References

1. S. A. Bhanu Pratap, Shamim Shamim, "Formulation and Characterisation of Herbal Ethosomal Gel of Luliconazole and Clove Oil for Modified Drug Diffusion to the Skin," *World J. Adv. Res. Rev.*, vol. 18, no. 4, pp. 488–501, 2025, doi: 10.1016/j.jaim.2024.100947.
2. H. J. Cha, C. He, H. Zhao, Y. Dong, I. S. An, and S. An, "Intercellular and intracellular functions of ceramides and their metabolites in skin (Review)," 2016. doi: 10.3892/ijmm.2016.2600.
3. I. Jahan, S. Ali, J. Hak, S. Shamim, M. Kumar, and T. Ali, "Emerging Trends in Magnetic Nanoparticle Delivery, Synthesis and Applications in Biomedicine," *Drug Deliv. Lett.*, vol. 16, no. 1, pp. 1–17, 2025, doi: 10.2174/0122103031400035251014115919.
4. B. M. Quinville, N. M. Deschenes, A. E. Ryckman, and J. S. Walia, "A comprehensive review: Sphingolipid metabolism and implications of disruption in sphingolipid homeostasis," 2021. doi: 10.3390/ijms22115793.
5. R. Singh, S. Shamim, S. Ali, R. Kumar, and T. Ali, "A Global Public Health Review of the Mumps Virus: Epidemiology, Pathogenesis, and Advances in Vaccination," *Anti-Infective Agents*, vol. 24, 2025, doi: 10.2174/0122113525412555250922164155.
6. Y. A. Hannun, A. H. Merrill, and C. Luberto, "The bioactive sphingolipid playbook. A primer for the uninitiated as well as sphingolipidologists," 2025. doi: 10.1016/j.jlr.2025.100813.
7. S. A. Ali, S. Ali, and S. Shamim, "Role of Artificial Intelligence in Transforming Diagnosis, Treatment, and Patient Care: A Review," *Curr. Pharmacogenomics Person. Med.*, vol. 23, 2025, doi: 10.2174/0118756921404728251019182202.
8. "Sphingolipid Signaling and Metabolism in Neuronal and Glial Cells: Implications for Cerebrovascular and Neurodegenerative Disorders," *aging Dis.*, 2025, doi: 10.14336/ad.2025.1024.
9. A. Anand et al., "Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management," *CNS Neurol. Disord. - Drug Targets*, vol. 24, no. 1, pp. 60–73, 2024, doi: 10.2174/0118715273332140240724093837.
10. H. Thakkar, V. Vincent, and B. Chaurasia, "Ceramide signaling in immunity: a molecular perspective," 2025. doi: 10.1186/s12944-025-02642-2.
11. S. A. Listian et al., "Complex sphingolipid profiling and identification of an inositol-phosphorylceramide synthase in *Dictyostelium discoideum*," *iScience*, 2024, doi: 10.1016/j.isci.2024.110609.
12. M. L. Fanani and B. Maggio, "The many faces (and phases) of ceramide and sphingomyelin I – single lipids," 2017. doi: 10.1007/s12551-017-0297-z.
13. T. Li et al., "The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system," 2026. doi: 10.1111/bpa.70033.
14. M. Gonzalez-Plascencia, I. Garza-Veloz, V. Flores-Morales, and M. L. Martinez-Fierro, "The Role of Ceramides in Metabolic and Cardiovascular Diseases," *J. Cardiovasc. Dev. Dis.*, 2026, doi: 10.3390/jcdd13010030.
15. E. Izquierdo et al., "Fluorescently Labeled Ceramides and 1-Deoxyceramides: Synthesis, Characterization, and Cellular Distribution Studies," *J. Org. Chem.*, 2022, doi: 10.1021/acs.joc.2c02019.
16. D. A. Ford, "A BOSSS platform: Using functionalized lipids and click chemistry for new discoveries in lipid research," 2021. doi: 10.1016/J.JLR.2021.100025.
17. S. Bockelmann et al., "A search for ceramide binding proteins using bifunctional lipid analogs yields CERT-related protein StarD7," *J. Lipid Res.*, 2018, doi: 10.1194/jlr.M082354.
18. C. D. Hunter, T. Guo, G. Daskhan, M. R. Richards, and C. W. Cairo, "Synthetic Strategies for Modified Glycosphingolipids and Their Design as Probes," 2018. doi: 10.1021/acs.chemrev.8b00070.

19. Y. Deng et al., "Identification of TRAMs as sphingolipid-binding proteins using a photoactivatable and clickable short-chain ceramide analog," *J. Biol. Chem.*, 2021, doi: 10.1016/j.jbc.2021.101415.
20. P. Haberkant et al., "Bifunctional Sphingosine for Cell-Based Analysis of Protein-Sphingolipid Interactions," *ACS Chem. Biol.*, 2016, doi: 10.1021/acscchembio.5b00810.
21. C. Wittenbecher et al., "Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology," *Nat. Commun.*, 2022, doi: 10.1038/s41467-022-28496-1.
22. D. Jamecna and D. Höglinger, "The use of click chemistry in sphingolipid research," 2024. doi: 10.1242/jcs.261388.
23. T. Xie et al., "Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid homeostasis," *Nat. Commun.*, 2023, doi: 10.1038/s41467-023-39274-y.
24. P. Kumar et al., "Fused Deposition Modeling 3D-Printed Scaffolds for Bone Tissue.pdf," *Appl. Biochem. Biotechnol.*, vol. 12, no. 22, pp. 1–11, 2024, doi: 10.54085/ap.2023.12.2.19.
25. N. Wajapeyee, T. C. Beamon, and R. Gupta, "Roles and therapeutic targeting of ceramide metabolism in cancer," 2024. doi: 10.1016/j.molmet.2024.101936.
26. Y. M. Shalaby, A. Al Aidaros, A. Valappil, B. R. Ali, and N. Akawi, "Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far," 2022. doi: 10.3389/fcell.2021.816301.
27. R. Klingenberg et al., "Ceramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets," 2025. doi: 10.1093/cvr/cvaf093.
28. K. Singh et al., "Emerging Applications and Innovations in Emulgel Technology for Enhanced Topical Drug Delivery," *Drug Deliv. Lett.*, vol. 15, pp. 1–16, 2025, doi: 10.2174/0122103031384904250930153320.
29. M. R. Bhise, V. Trivedi, S. Devi, A. Kumar, T. Jayendra, and K. Sunand, "Graphene Quantum Dots in Cancer Diagnostics and Therapeutics: Advances in Biosensing, Imaging, and Treatment Applications," *Curr. Med. Sci.*, vol. 46, no. 1, pp. 20–33, 2025, doi: 10.1007/s11596-025-00155-8.
30. A. T. Arias-Marroquín et al., "Modulation of ceramides through nutrition: A new target in obesity and insulin resistance (Narrative Review)," 2026. doi: 10.1016/j.clnesp.2025.11.156.
31. J. Alizadeh et al., "Ceramides and ceramide synthases in cancer: Focus on apoptosis and autophagy," *Eur. J. Cell Biol.*, 2023, doi: 10.1016/j.ejcb.2023.151337.
32. J. J. McInnis et al., "Unravelling neuronal and glial differences in ceramide composition, synthesis, and sensitivity to toxicity," *Commun. Biol.*, 2024, doi: 10.1038/s42003-024-07231-0.
33. I. Alexandropoulou et al., "Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment," 2023. doi: 10.3390/nu15010229.
34. P. Baker, C. Huang, R. Radi, S. B. Moll, E. Jules, and J. L. Arbiser, "Skin Barrier Function: The Interplay of Physical, Chemical, and Immunologic Properties," 2023. doi: 10.3390/cells12232745.
35. H. Shu, Y. Peng, W. Hang, N. Li, N. Zhou, and D. W. Wang, "Emerging Roles of Ceramide in Cardiovascular Diseases," 2022. doi: 10.14336/AD.2021.0710.
36. K. Singh et al., "Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders," *Curr. Top. Med. Chem.*, vol. 24, no. 22, pp. 1940–1959, 2024, doi: 10.2174/0115680266305736240725052825.
37. E. Usta et al., "The challenge to verify ceramide's role of apoptosis induction in human cardiomyocytes - a pilot study," *J. Cardiothorac. Surg.*, 2011, doi: 10.1186/1749-8090-6-38.
38. A. Cogolludo, E. Villamor, F. Perez-Vizcaino, and L. Moreno, "Ceramide and regulation of vascular tone," 2019. doi: 10.3390/ijms20020411.
39. R. Spaggiari et al., "Ceramides as Emerging Players in Cardiovascular Disease: Focus on Their Pathogenetic Effects and Regulation by Diet," 2024. doi: 10.1016/j.advnut.2024.100252.
40. E. Michelucci, S. Rocchiccioli, M. Gaggini, R. Ndreu, S. Berti, and C. Vassalle, "Ceramides and Cardiovascular Risk Factors, Inflammatory Parameters and Left Ventricular Function in AMI Patients," *Biomedicines*, 2022, doi: 10.3390/biomedicines10020429.
41. S. et al. Singh, K., Gupta, J. K., Chanchal, D. K., Khan, S., Varma, A., Shanno, K., Kumar, S., & Shamim, "Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus," *Curr. Pharmacogenomics Person. Med.*, vol. 21, no. 3, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
42. H. Yuan, B. Zhu, C. Li, and Z. Zhao, "Ceramide in cerebrovascular diseases," 2023. doi: 10.3389/fncel.2023.1191609.
43. M. R. Khan, D. Kumar, S. Shamim, K. Sunand, S. Sharma, and G. Rawat, "Ethnopharmacological relevance of Citrus limon (L.) Burm. f. as adjuvant therapy," *Ann. Phytomedicine An Int. J.*, vol. 12, no. 2, pp. 169–179, 2023, doi: 10.54085/ap.2023.12.2.19.
44. N. Mandal, R. Gramberg, K. Mondal, S. K. Basu, F. Tahia, and S. Dagogo-Jack, "Role of ceramides in the pathogenesis of diabetes mellitus and its complications," 2021. doi: 10.1016/j.jdiacomp.2020.107734.
45. A. Dilip, R. Akash, L. Thangavelu, and R. P. Parameswari, "Exploring the Role of Ceramides by Elisa Analysis: Orchestrating the Pathogenesis of Diabetes Mellitus and its Complications," *Texila Int. J. Public Heal.*,

- 2024, doi: 10.21522/TIJPH.2013.12.03.Arto66.
46. Shamim, S. Ali, T. Ali, H. Sharma, B. N. Kishor, and S. K. Jha, "Recent Advances in Monodisperse Gold Nanoparticle Delivery, Synthesis, and Emerging Applications in Cancer Therapy," *Plasmonics*, vol. 20, no. 1, pp. 7121–7141, 2025, doi: 10.1007/s11468-024-02732-4.
47. P. Hammerschmidt and J. C. Brüning, "Contribution of specific ceramides to obesity-associated metabolic diseases," 2022. doi: 10.1007/s00018-022-04401-3.
48. E. Hajduch, F. Lachkar, P. Ferré, and F. Foulle, "Roles of ceramides in non-alcoholic fatty liver disease," 2021. doi: 10.3390/jcm10040792.
49. M. Sheridan and B. Ogretmen, "The role of ceramide metabolism and signaling in the regulation of mitophagy and cancer therapy," 2021. doi: 10.3390/cancers13102475.
50. A. Shrivastava et al., "Heart Failure Management in the Modern Era: A Comprehensive Review on Medical and Device-based Interventions," *Curr. Cardiol. Rev.*, vol. 21, no. 6, pp. 1–14, 2025, doi: 10.2174/011573403x338702250226075044.
51. P. Pal, G. E. Atilla-Gokcumen, and J. Frasor, "Emerging Roles of Ceramides in Breast Cancer Biology and Therapy," 2022. doi: 10.3390/ijms231911178.
52. M. Radha et al., "Stimuli-Responsive Carbon Nanotubes for On-Demand Cancer Therapy: A Review," *AAPS PharmSciTech*, vol. 27, no. 1, pp. 1–31, 2026, doi: 10.1208/s12249-026-03391-w.
53. N. Merz, J. C. Hartel, and S. Grösch, "How ceramides affect the development of colon cancer: from normal colon to carcinoma," 2024. doi: 10.1007/s00424-024-02960-x.
54. R. Ahmad et al., "Mechanistic insights into the neuroprotective effects of Radix Astragali (Huang Qi): Bridging Traditional Chinese Medicine and modern pharmacology," *Pharmacol. Res. - Mod. Chinese Med.*, vol. 17, no. July, p. 100711, 2025, doi: 10.1016/j.prmm.2025.100711.
55. X. Shen, R. Feng, R. Zhou, Z. Zhang, K. Liu, and S. Wang, "Ceramide as a Promising Tool for Diagnosis and Treatment of Clinical Diseases: A Review of Recent Advances," 2025. doi: 10.3390/metabo15030195.
56. H. O. Kalkman and L. Smigielski, "Ceramides may Play a Central Role in the Pathogenesis of Alzheimer's Disease: a Review of Evidence and Horizons for Discovery," 2025. doi: 10.1007/s12035-025-04989-0.
57. M. Vos, C. Klein, and A. A. Hicks, "Role of Ceramides and Sphingolipids in Parkinson's Disease," *J. Mol. Biol.*, 2023, doi: 10.1016/j.jmb.2023.168000.
58. K. Sunand, A. K. Tripathi, A. Patel, P. Nasa, S. Ali, and S. Shamim, "Mechanistic Insights and Therapeutic Advances in Natural Bioactive Compounds as Multi-target Agents in Rheumatoid Arthritis," *Curr. Rheumatol. Rev.*, pp. 1–19, 2026, doi: 10.2174/0115733971409871251206061614.
59. K. Castro et al., "Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course," *EBioMedicine*, 2019, doi: 10.1016/j.ebiom.2019.03.087.
60. J. S. Jung et al., "Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide-stimulated microglia," *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids*, 2013, doi: 10.1016/j.bbalip.2013.01.020.
61. M. R. Chowdhury, H. K. Jin, and J. S. Bae, "Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer's Disease," 2022. doi: 10.3390/biomedicines10081956.
62. A. K. Jaiswal et al., "Multi-targeted therapeutic exploration of Tamarix gallica flowers for anti-ulcer activity and associated complications," *J. Ayurveda Integr. Med.*, vol. 15, no. 4, p. 100947, 2024, doi: 10.1016/j.jaim.2024.100947.
63. J. T. Ke et al., "Metabonomic analysis of abnormal sphingolipid metabolism in rheumatoid arthritis synovial fibroblasts in hypoxia microenvironment and intervention of geniposide," *Front. Pharmacol.*, 2022, doi: 10.3389/fphar.2022.969408.
64. K. Singh et al., "Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus," *Curr. Pharmacogenomics Person. Med.*, vol. 21, no. 3, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
65. Y. Li, R. J. Nicholson, and S. A. Summers, "Ceramide signaling in the gut," 2022. doi: 10.1016/j.mce.2022.111554.
66. A. Gomez-Larrauri, A. Larrea-Sebal, C. Martín, and A. Gomez-Muñoz, "The critical roles of bioactive sphingolipids in inflammation," 2025. doi: 10.1016/j.jbc.2025.110475.
67. B. N. James et al., "Ceramide in apoptosis and oxidative stress in allergic inflammation and asthma," *J. Allergy Clin. Immunol.*, 2021, doi: 10.1016/j.jaci.2020.10.024.
68. T. Shamim, Ali, "Chromatography and Spectroscopic Characterization of Nano-Carrier Pharmaceuticals," *Pharm. Nanotechnol.*, vol. 14, no. 2, pp. 176–190, 2024, doi: 10.2174/0122117385319695240911115239.
69. K. R. Feingold and P. M. Elias, "The role of ceramides in the disruption of the cutaneous permeability barrier, a common manifestation of skin disorders," 2024. doi: 10.1016/j.jlr.2024.100593.
70. M. Fujii, "The pathogenic and therapeutic implications of ceramide abnormalities in atopic dermatitis," 2021. doi: 10.3390/cells10092386.
71. Q. Li, H. Fang, E. Dang, and G. Wang, "The role of ceramides in skin homeostasis and inflammatory skin diseases," 2020. doi: 10.1016/j.jdermsci.2019.12.002.
72. J. L. Stith, F. N. Velazquez, and L. M. Obeid, "Advances in determining signaling mechanisms of ceramide and role in disease," 2019. doi: 10.1194/jlr.S092874.
73. H. Sharma, A. P. Singh, D. Pathak, D. Taumar, and V. Chaudhary, "The Role of approved Kinase Inhibitors in Cancer Treatment :

- Medicinal Chemistry and Pharmacological Insights,” *Med. Chem. (Los. Angeles).*, pp. 1–18, 2025, doi: 10.2174/0115734064404334251024112120.
74. Z. Li, L. Zhang, D. Liu, and C. Wang, “Ceramide glycosylation and related enzymes in cancer signaling and therapy,” 2021. doi: 10.1016/j.biopha.2021.111565.
 75. P. Vishvakarma et al., “Nanocarrier Mediated Delivery of Gepotidacin: A Novel Triazaacenaph- thylene Antibiotic Targeting Drug-Resistant Bacterial Infections,” *Anti-Infective Agents*, vol. 14, no. 3, pp. 1–18, 2026, doi: 10.2174/0122113525430497251211145738.
 76. A. Gomez-Larrauri, A. Benito-Vicente, A. Larrea-Sebal, C. Martín, and A. Gomez-Muñoz, “Role of Ceramide Kinase/C1P in the Regulation of Cell Growth and Survival,” 2025. doi: 10.3390/ijms26178374.
 77. H. Hua et al., “Remodeling ceramide homeostasis promotes functional maturation of human pluripotent stem cell-derived β cells,” *Cell Stem Cell*, 2024, doi: 10.1016/j.stem.2024.04.010.
 78. S. Ding et al., “Ceramides and mitochondrial homeostasis,” *Cell. Signal.*, 2024, doi: 10.1016/j.cellsig.2024.111099.
 79. J. Kumar et al., “CFTR mRNA-Based Gene Therapy for Cystic Fibrosis: A Mutation-Agnostic Strategy to Restore Ion Transport Function,” *Curr. Gene Ther.*, pp. 1–18, 2025, doi: 10.2174/0115665232413980251103133741.
 80. Y. Pan et al., “A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer’s disease, and their co-morbidities,” 2024. doi: 10.3389/fphar.2024.1348410.
 81. M. Piccoli et al., “Sphingolipids and Atherosclerosis: The Dual Role of Ceramide and Sphingosine-1-Phosphate,” 2023. doi: 10.3390/antiox12010143.
 82. M. MacEyka and S. Spiegel, “Sphingolipid metabolites in inflammatory disease,” 2014. doi: 10.1038/nature13475.
 83. A. P. Singh et al., “Revolutionizing Drug and Gene Delivery: Cutting-Edge Smart Polymers for Precision Release,” *Curr. Gene Ther.*, vol. 26, no. 1, pp. 1–19, 2025, doi: 10.2174/0115665232390238251121074917.
 84. W. J. Van Blitterswijk, A. H. Van Der Luit, R. J. Veldman, M. Verheij, and J. Borst, “Ceramide: Second messenger or modulator of membrane structure and dynamics?,” 2003. doi: 10.1042/BJ20021528.
 85. P. Chandel, S. Shamim, and S. Ali, “A Comprehensive Review on Nanoemulsions for Improved Bioavailability and Therapeutic Efficacy in Gastrointestinal Disorders,” *Drug Deliv. Lett.*, pp. 1–18, 2021, doi: 10.2174/0122103031410345251205075031.
 86. D. C. Pant, S. Aguilera-Albesa, and A. Pujol, “Ceramide signalling in inherited and multifactorial brain metabolic diseases,” 2020. doi: 10.1016/j.nbd.2020.105014.
 87. G. M. R. S. Grelle et al., “Characterization of Ceramide Kinase from Basolateral Membranes of Kidney Proximal Tubules: Kinetics, Physicochemical Requirements, and Physiological Relevance,” *Int. J. Mol. Sci.*, 2025, doi: 10.3390/ijms262110373.
 88. P. Kumar et al., “Trends of Nanobiosensors in Modern Agriculture Systems,” *Appl. Biochem. Biotechnol.*, vol. 197, no. 1, pp. 667–690, 2024, doi: 10.1007/s12010-024-05039-6.
 89. Y. Huo et al., “Ceramide mediates cell-to-cell ER stress transmission by modulating membrane fluidity,” *J. Cell Biol.*, 2025, doi: 10.1083/jcb.202405060.
 90. F. Li and N. Zhang, “Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment,” *Curr. Drug Metab.*, 2015, doi: 10.2174/1389200216666151103120338.
 91. A. Ciner et al., “A phase I study of the ceramide nanoliposome in patients with advanced solid tumors,” *Cancer Chemother. Pharmacol.*, 2024, doi: 10.1007/s00280-023-04588-7.
 92. A. Gomez-Larrauri, U. Das Adhikari, M. Aramburu-Nuñez, A. Custodia, and A. Ouro, “Ceramide metabolism enzymes—therapeutic targets against cancer,” 2021. doi: 10.3390/medicina57070729.
 93. S. A. Ali, S. Ali, S. Rastogi, B. Shivhare, and M. Muztaba, “A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics,” *Micro Nanosyst.*, vol. 17, no. 4, pp. 283–297, 2025, doi: 10.2174/0118764029358553250325040749.
 94. M. Gaggini, R. Ndreu, E. Michelucci, S. Rocchiccioli, and C. Vassalle, “Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease,” 2022. doi: 10.3390/ijms23052719.
 95. F. Al-Rashed et al., “Ceramide kinase regulates TNF- α -induced immune responses in human monocytic cells,” *Sci. Rep.*, 2021, doi: 10.1038/s41598-021-87795-7.
 96. P. L. Li and Y. Zhang, “Cross talk between ceramide and redox signaling: Implications for endothelial dysfunction and renal disease,” *Handb. Exp. Pharmacol.*, 2013, doi: 10.1007/978-3-7091-1511-4_9.
 97. O. Fonseka et al., “Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential,” 2025. doi: 10.3390/cells14050324.
 98. M. B. Lorey, K. Öörni, and P. T. Kovanen, “Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis,” 2022. doi: 10.3389/fcvm.2022.841545.
 99. S. Chawla, R. Gupta, S. K. Jha, and K. T. Jha, “Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and Conformational Isomers,” *Med. Chem. (Los. Angeles).*, 2025, doi: 10.2174/0115734064366389250923044201.
 100. S. Wang, Z. Jin, B. Wu, A. J. Morris, and P. Deng, “Role of dietary and nutritional interventions in ceramide-associated diseases,” 2025. doi: 10.1016/j.jlrl.2024.100726.
 101. J. Kumar et al., “Stimuli-responsive Hydrogels

- for Targeted Antibiotic Delivery in Bone Tissue Engineering,” *AAPS PharmSciTech*, vol. 26, no. 217, pp. 1–23, 2025, doi: <https://doi.org/10.1208/s12249-025-03218-0>.
102. A. Reginato et al., “The role of fatty acids in ceramide pathways and their influence on hypothalamic regulation of energy balance: a systematic review,” *Int. J. Mol. Sci.*, 2021, doi: 10.3390/ijms22105357.
103. J. Guo, J. Feng, H. Qu, H. Xu, and H. Zhou, “Potential Drug Targets for Ceramide Metabolism in Cardiovascular Disease,” 2022, doi: 10.3390/jcdd9120434.
104. E. Młynarska et al., “The Mediterranean Diet in Primary and Secondary Prevention of Coronary Heart Disease: Evidence and Mechanisms,” 2025, doi: 10.3390/nu17223617.
105. A. Wretling et al., “Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes,” *Diabetes*, 2023, doi: 10.2337/db23-0052.